Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Efficacy and Safety of BMSCs (CG-BM1) for ACLF Patients — Stella

Home/Acute-On-Chronic Liver Failure/Efficacy and Safety of BMSCs (CG-BM1) for ACLF Patients

View on ClinicalTrials.gov

Recruiting

Back to Acute-On-Chronic Liver Failure trials

Efficacy and Safety of BMSCs (CG-BM1) for ACLF Patients

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Third Affliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong

Key details

Phase

Early testing / Safety & dosing

Sponsor

Sun Yat-sen University

Collaborators

Guangzhou Cellgenes Biotechnology Co.,Ltd

Enrollment target

~90 participants

Started

March 2023

Primary completion

October 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated December 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.